LON:SAR Sareum (SAR) Share Price, News & Analysis GBX 21.40 +0.40 (+1.90%) As of 05/15/2026 10:18 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsInsider TradesBuy This Stock About Sareum Stock (LON:SAR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sareum alerts:Sign Up Key Stats Today's Range 20▼ 2250-Day Range 13.33▼ 21.9452-Week Range 9.50▼ 29Volume110,206 shsAverage Volume228,078 shsMarket Capitalization£29.55 millionP/E RatioN/ADividend Yield1.10%Price TargetN/AConsensus RatingN/A Company Overview Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage. Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802). Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients. SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance. Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company’s website at www.sareum.com Read More Receive SAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sareum and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SAR Stock News HeadlinesWe're Keeping An Eye On Sareum Holdings' (LON:SAR) Cash Burn RateApril 6, 2026 | finance.yahoo.comSareum Holdings Passes All Resolutions at AGM, Strengthening GovernanceDecember 9, 2025 | tipranks.comForget SpaceX. Buy the company Musk can't replace.The SpaceX IPO is expected to price at $1.75 trillion - and retail investors won't get an allocation. Banks and insiders have already locked it up. But there is one small, publicly traded company that builds the critical infrastructure SpaceX cannot operate without. Dylan Jovine is releasing the ticker name today at no cost.May 16 at 1:00 AM | Behind the Markets (Ad)AIM WINNERS & LOSERS: Sareum halts study over control group issuesOctober 10, 2025 | lse.co.ukSareum falls after safety study halted over animal welfare concernsOctober 10, 2025 | lse.co.ukSareum Holdings Increases Share Capital Through Warrant ExerciseSeptember 18, 2025 | tipranks.comSareum Holdings Expands Share Capital Through Warrant ExerciseAugust 26, 2025 | tipranks.comSareum shares climb on partnership with AI-driven drug discovery firmAugust 12, 2025 | lse.co.ukSee More Headlines SAR Stock Analysis - Frequently Asked Questions How have SAR shares performed this year? Sareum's stock was trading at GBX 14.92 at the beginning of 2026. Since then, SAR stock has increased by 43.4% and is now trading at GBX 21.40. How were Sareum's earnings last quarter? Sareum Holdings plc (LON:SAR) posted its quarterly earnings results on Thursday, March, 12th. The company reported ($1.20) EPS for the quarter. How do I buy shares of Sareum? Shares of SAR stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Sareum own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sareum investors own include ReNeuron Group (RENE), ValiRx (VAL), Egdon Resources (EDR), Collagen Solutions plc (COS.L) (COS), Gulf Keystone Petroleum (GKP) and Summit Therapeutics (SMMT). Company Calendar Last Earnings3/12/2026Today5/16/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryFinancial Services Current SymbolLON:SAR CIKN/A Webwww.sareum.co.uk Phone+44-1223-497700FaxN/AEmployees3,211Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (3.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£5.28 million Net MarginsN/A Pretax MarginN/A Return on Equity-284.01% Return on Assets-113.80% Debt Debt-to-Equity RatioN/A Current Ratio1.59 Quick Ratio10.37 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 1.89 per share Price / Cash Flow11.32 Book ValueGBX 2.61 per share Price / Book8.20Miscellaneous Outstanding Shares138,065,000Free FloatN/AMarket Cap£29.55 million OptionableNot Optionable Beta-1.08 The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (LON:SAR) was last updated on 5/16/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredOil is settling in yuan now - here's what that means for goldSaudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sareum Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Sareum With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
